Illumina, Inc. vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Illumina, Inc. trades at $264.62 (market cap $40.43B), while YieldMax MSTR Option Income Strategy ETF trades at $15.73 (market cap $1.11B). The key difference: Illumina, Inc. is far larger — about 36.4× YieldMax MSTR Option Income Strategy ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and YieldMax MSTR Option Income Strategy ETF for 30 Days on average.
| ILMN | MSTY | |
|---|---|---|
Market Cap | $40.43B | $1.11B |
Volume | 2,948,626 | 3,805,384 |
Sector | Health | Income / Options Overlay |
52-Week High | $293.69 | $67.85 |
52-Week Low | $91.00 | $11.55 |
Typical Hold Time | 83 Days | 30 Days |
Enterprise Value | $41.79B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
MSTY, the YieldMax MSTR Option Income Strategy ETF, trades at $15.83, down 5.61% with a bearish technical signal. The fund generates weekly distributions through options strategies on MicroStrategy stock, with recent payouts ranging from $0.16 to $0.34. Despite high distribution rates exceeding 100% annualized, the fund has experienced significant NAV erosion, declining approximately 34% over six months according to 24/7 Wall Street analysis from July 2026.
The outlook remains challenging as MSTY's strategy sacrifices capital appreciation for income generation. While the high distribution rate provides income, the structural erosion of NAV presents substantial risk. Investors face the dual challenge of receiving taxable distributions while experiencing principal decline, making this suitable only for those prioritizing current income over capital preservation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →